消除C型肝炎最關鍵的一哩路：注射藥物族群的防治現況與建議

吳慧敏、楊雯雯、劉嘉玲等：台灣2025年C肝消除的策略與進度。台灣衛誌 2021；40：1-4。doi:10.6288/TJPH.202102_40(1).PF01。 Wu GH, Yang WW, Liu CL, et al. Eliminating hepatitis C in Taiwan by 2025: strategies and progress. Taiwan J Public Health 2021;40:1-4. doi:10.6288/TJPH.202102_40(1).PF01. [In Chinese]

Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98. doi:10.1056/NEJMoa1402454

Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-92. doi:10.1056/NEJMoa1402338

Wu GH, Pwu RF, Chen SC. Achieving hepatitis C elimination in Taiwan -- overcoming barriers by setting feasible strategies. J Formos Med Assoc 2018;117:1044-5. doi:10.1016/j.jfma.2018.10.021

Lazarus JV, Wiktor S, Colombo M, Thursz M; EASL International Liver Foundation. Micro-elimination - a path to global elimination of hepatitis C. J Hepatol 2017;67:665-6. doi:10.1016/j.jhep.2017.06.033

主題瀏覽

消除C型肝炎最關鍵的一哩路：注射藥物族群的防治現況與建議

The most critical mile to eliminate hepatitis C: Current status and recommendations for the prevention and treatment of people who inject drugs

參考文獻

延伸閱讀

本網站使用Cookies